Instituto Cajal Of Neurobiologia

Madrid, Spain

Instituto Cajal Of Neurobiologia

Madrid, Spain
SEARCH FILTERS
Time filter
Source Type

Chacon P.J.,Centro Andaluz Of Biologia Molecular Y Medicina Regenerativa | Arevalo M.A.,Instituto Cajal Of Neurobiologia | Tebar A.R.,Centro Andaluz Of Biologia Molecular Y Medicina Regenerativa
Molecular and Cellular Neuroscience | Year: 2010

NGF diminishes dendrite complexity in cultured hippocampal neurons by decreasing the number of primary and secondary dendrites, while increasing the length of those that remain. The transduction pathway used by NGF to provoke dendrite elongation involves the activation of NF-κ-B and the expression of the homologues of Enhancer-of-split 1 gene. Here, we define important steps that link NGF with NF-κ-B activation, through the activity of protein tyrosine phosphatase 1B (PTP1B). Binding of NGF to p75NTR stimulates PTP1B activity, which can be blocked by either pharmacological inhibition of the phosphatase or by transfecting neurons with a dn PTP1B isoform, whereby NGF is no longer able to stimulate dendrite growth. Indeed, overexpressing PTP1B alone provoked dendrite growth and further studies revealed a role for the src kinase downstream of PTP1B. Again, loss of src activity largely cancelled out the capacity of NGF to promote dendrite growth, whereas overexpression of v-src in neurons was sufficient to promote dendrite growth. Finally, the NGF/p75NTR/PTP1B/src kinase pathway led to the tyrosine phosphorylation of I-κ-Bα prior to its degradation, an event that is necessary for NF-κ-B activation. Indeed, the dendrite growth response to NGF was lost when neurons were transfected with a mutant form of I-κ-Bα that lacks tyr42. Thus, our data suggest that PTP1B fulfils a central role in the NGF signalling that controls dendrite patterning in hippocampal neurons. © 2010 Elsevier Inc. All rights reserved.


Romero-Ramirez L.,Hospital Nacional Of Paraplejicos | Romero-Ramirez L.,Instituto Cajal Of Neurobiologia | Garcia-Alvarez I.,Hospital Nacional Of Paraplejicos | Garcia-Alvarez I.,Institute Quimica Organica General | And 6 more authors.
PLoS ONE | Year: 2012

Gangliosides are sialic acid containing glycosphingolipids, commonly found on the outer leaflet of the plasma membrane. O-acetylation of sialic acid hydroxyl groups is one of the most common modifications in gangliosides. Studies on the biological activity of O-acetylated gangliosides have been limited by their scarcity in nature. This comparatively small change in ganglioside structure causes major changes in their physiological properties. When the ganglioside GD1b was O-acetylated in the outer sialic acid, it became the potent inhibitor of astroblast and astrocytoma proliferation called Neurostatin. Although various chemical and enzymatic methods to O-acetylate commercial gangliosides have been described, O-acetylation was nonspecific and produced many side-products that reduced the yield. An enzyme with O-acetyltransferase activity (SOAT) has been previously cloned from the bacteria Campylobacter jejuni. This enzyme catalyzed the acetylation of oligosaccharide-bound sialic acid, with high specificity for terminal alpha-2,8-linked residues. Using this enzyme and commercial gangliosides as starting material, we have specifically O-acetylated the gangliosides' outer sialic acids, to produce the corresponding gangliosides specifically O-acetylated in the sialic acid bound in alpha-2,3 and alpha-2,8 residues. We demonstrate here that O-acetylation occurred specifically in the C-9 position of the sialic acid. In summary, we present a new method of specific O-acetylation of ganglioside sialic acids that permits the large scale preparation of these modified glycosphingolipids, facilitating both, the study of their mechanism of antitumoral action and their use as therapeutic drugs for treating glioblastoma multiform (GBM) patients. © 2012 Romero-Ramírez et al.


Garcia-Alvarez I.,Hospital Nacional Of Paraplejicos | Garcia-Alvarez I.,Institute Quimica Organica General | Garrido L.,CSIC - Institute of Polymer Science and Technology | Romero-Ramirez L.,Hospital Nacional Of Paraplejicos | And 5 more authors.
PLoS ONE | Year: 2013

The effect of the treatment with glycolipid derivatives on the metabolic profile of intact glioma cells and tumor tissues, investigated using proton high resolution magic angle spinning (1H HR-MAS) nuclear magnetic resonance (NMR) spectroscopy, is reported here. Two compounds were used, a glycoside and its thioglycoside analogue, both showing anti-proliferative activity on glioma C6 cell cultures; however, only the thioglycoside exhibited antitumor activity in vivo. At the drug concentrations showing anti-proliferative activity in cell culture (20 and 40 μM), significant increases in choline containing metabolites were observed in the 1H NMR spectra of the same intact cells. In vivo experiments in nude mice bearing tumors derived from implanted C6 glioma cells, showed that reduction of tumor volume was associated with significant changes in the metabolic profile of the same intact tumor tissues; and were similar to those observed in cell culture. Specifically, the activity of the compounds is mainly associated with an increase in choline and phosphocholine, in both the cell cultures and tumoral tissues. Taurine, a metabolite that has been considered a biomarker of apoptosis, correlated with the reduction of tumor volume. Thus, the results indicate that the mode of action of the glycoside involves, at least in part, alteration of phospholipid metabolism, resulting in cell death. © 2013 García-Álvarez et al.


Nieto-Sampedro M.,Instituto Cajal Of Neurobiologia | Nieto-Sampedro M.,Hospital Nacional Of Paraplejicos | Valle-Argos B.,Instituto Cajal Of Neurobiologia | Valle-Argos B.,Hospital Nacional Of Paraplejicos | And 4 more authors.
Clinical Medicine Insights: Oncology | Year: 2011

Treated glioblastoma patients survive from 6 to 14 months. In the first part of this review, we describe glioma origins, cancer stem cells and the genomic alterations that generate dysregulated cell division, with enhanced proliferation and diverse response to radiation and chemotherapy. We review the pathways that mediate tumour cell proliferation, neo-angiogenesis, tumor cell invasion, as well as necrotic and apoptotic cell death. Then, we examine the ability of gliomas to evade and suppress the host immune system, exhibited at the levels of antigen recognition and immune activation, limiting the effective signaling between glioma and host immune cells. The second part of the review presents current therapies and their drawbacks. This is followed by a summary of the work of our laboratory during the past 20 years, on oligosaccharide and glycosphingolipid inhibitors of astroblast and astrocytoma division. Neurostatins, the O-acetylated forms of gangliosides GD1b and GT1b naturally present in mammalian brain, are cytostatic for normal astroblasts, but cytotoxic for rat C6 glioma cells and human astrocytoma grades III and IV, with ID50 values ranging from 200 to 450 nM. The inhibitors do not affect neurons or fibroblasts up to concentrations of 4 μM or higher. At least four different neurostatin-activated, cell-mediated antitumoral processes, lead to tumor destruction: (i) inhibition of tumor neovascularization; (ii) activation of microglia; (iii) activation of natural killer (NK) cells; (iv) activation of cytotoxic lymphocytes (CTL). The enhanced antigenicity of neurostatin-treated glioma cells, could be related to their increased expression of connexin 43. Because neurostatins and their analogues show specific activity and no toxicity for normal cells, a clinical trial would be the logical next step. © the author(s), publisher and licensee Libertas Academica Ltd.


PubMed | Instituto Cajal Of Neurobiologia
Type: Journal Article | Journal: Expert opinion on therapeutic patents | Year: 2011

Neurostatin, a natural glycosphingolipid inhibitor of astroblast and astrocytoma division, present in mammalian brain, is the modified ganglioside O-acetylated GD1b. It is cytostatic for rat astroblasts, C6 glioma cells and various human astrocytoma lines grades III and IV, with median inhibitory dose values ranging 1 - 5 M. Neurostatin was shown not to affect primary or transformed fibroblast division at concentrations of 10 M. A synthetic neurostatin analogue, NF-115, consisting of an octyl N-acetylglucosaminide derivative with a pentaerythritol chain at position 6, loaded on a slow-delivery polymer disc, caused the destruction of cultured human astroblastoma, obtained after surgical biopsy, and destroyed human neuroectodermic tumours implanted in rats and human astrocytoma implanted in immunodeficient mice. Future antitumourals should combine the high activity of neurostatin with the ease of synthesis of NF-115.


PubMed | Instituto Cajal Of Neurobiologia
Type: | Journal: Clinical Medicine Insights. Oncology | Year: 2011

Treated glioblastoma patients survive from 6 to 14 months. In the first part of this review, we describe glioma origins, cancer stem cells and the genomic alterations that generate dysregulated cell division, with enhanced proliferation and diverse response to radiation and chemotherapy. We review the pathways that mediate tumour cell proliferation, neo-angiogenesis, tumor cell invasion, as well as necrotic and apoptotic cell death. Then, we examine the ability of gliomas to evade and suppress the host immune system, exhibited at the levels of antigen recognition and immune activation, limiting the effective signaling between glioma and host immune cells.The second part of the review presents current therapies and their drawbacks. This is followed by a summary of the work of our laboratory during the past 20 years, on oligosaccharide and glycosphingolipid inhibitors of astroblast and astrocytoma division. Neurostatins, the O-acetylated forms of gangliosides GD1b and GT1b naturally present in mammalian brain, are cytostatic for normal astroblasts, but cytotoxic for rat C6 glioma cells and human astrocytoma grades III and IV, with ID50 values ranging from 200 to 450 nM. The inhibitors do not affect neurons or fibroblasts up to concentrations of 4 M or higher.At least four different neurostatin-activated, cell-mediated antitumoral processes, lead to tumor destruction: (i) inhibition of tumor neovascularization; (ii) activation of microglia; (iii) activation of natural killer (NK) cells; (iv) activation of cytotoxic lymphocytes (CTL). The enhanced antigenicity of neurostatin-treated glioma cells, could be related to their increased expression of connexin 43. Because neurostatins and their analogues show specific activity and no toxicity for normal cells, a clinical trial would be the logical next step.

Loading Instituto Cajal Of Neurobiologia collaborators
Loading Instituto Cajal Of Neurobiologia collaborators